Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer (TOBACO): a Randomized, Controlled, Phase II Study

NCT05077839 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05077839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer (TOBACO): a Randomized, Controlled, Phase II Study
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2021
Completion date
August 31, 2025
Enrollment
184 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer, first-line treatment